Leiden, Netherlands , March 13, 2024 /PRNewswire/ — ProteoNic Biosciences, a leading provider of premium vector technologies and services for biopharmaceutical manufacturing, today announced its partnership with Ginkgo Bioworks (NYSE: DNA), which is building a leading platform for cell programming and biosecurity. announced a partnership. This strategic alliance will give Ginkgo Bioworks' customers access to his ProteoNic's cutting-edge vector technology in the protein production field and novel viral vector technology for cell and gene therapy applications. This also means that ProteoNic will join the Ginkgo Technology Network, an innovative ecosystem of cutting-edge technology partners dedicated to driving innovation in their customers' R&D programs.

“This collaboration presents significant opportunities for ProteoNic and its customers,” he says. Frank Pieper, CEO of Proteonic. “This partnership will enable the production of complex biologics and support clients in achieving capacity improvements and cost reductions in biologics manufacturing, while also addressing significant hurdles in viral vector manufacturing for cell and gene therapy. It aligns seamlessly with our core mission:

ProteoNic's premium vector technology is widely applicable across cell lines and product classes, including complex molecules that are difficult to express using traditional techniques. The application of this new technology allows complex molecules to be produced at economically viable levels, solving capacity constraints and reducing manufacturing costs. When applied to viral vectors, it could solve the bottlenecks currently associated with LV and AAV production.

Ginkgo Technology Network brings together diverse partners across AI, genetic medicine, biologics, and manufacturing, integrating each partner's capabilities to provide customers with robust end-to-end solutions for successful research and development outcomes. is intended to provide.

“I have known and respected the ProteoNic team for several years and am excited to welcome them to the Ginkgo Technology Network,” he said. anna marie wagner, SVP, Head of AI and Corporate Development at Ginkgo. “Their expertise and superior technology will add tremendous value to our network and strengthen our ability to provide comprehensive solutions to our customers across a variety of biotechnology sectors.”

About Proteonic BV

ProteoNic is a privately held company with offices in Leiden. Netherlands and in that boston area, united states of america. The company provides technology and services for the generation of cell lines and viral vectors with significantly improved production characteristics. The company commercializes its proprietary 2GUNic® technology through licensing and partnership arrangements.

For more information, please visit www.proteonic.nl.

About Ginko Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, offering flexible end-to-end services to solve organizational challenges across diverse markets, from food and agriculture to pharmaceuticals and industrial and specialty chemicals. I am. Concentric by Ginkgo, Ginkgo's biosecurity and public health division, is the global leader in biosecurity, empowering governments, communities, and public health leaders to prevent, detect, and respond to a wide range of biological threats. We are building a new infrastructure. For more information, visit www.ginkgobioworks.com and www.concentricbyginkgo.com, read our blog, or follow us on our social media channels including X (formerly Twitter) (@Ginkgo and @ConcentricByGBW) and Instagram (@GinkgoBioworks) please. , threads (@GinkgoBioworks) or LinkedIn.

For more information, please contact us below.

Proteonic BV

Mark Posno,PhD
Vice President of Business Development
Phone: +1 617 480 8016
E: [email protected]

Logo: https://mma.prnewswire.com/media/1804728/ProteoNic_Logo.jpg

Source Proteonic



Source link